This resulted in two multiplex assays, one for BRAF and KRAS mutations and one for PIK3CA and NRAS. The performance of the assays was tested on 294 CRC samples that had been sequenced for mutations in KRAS exon 2 and was found to be superior to sequencing. Here, PIK3CA is linked to colorectal carcinoma.